Genitourinary Cancers

New Imaging Techniques in Prostate Cancer.- Targeted ablative therapies for prostate cancer.-  Prostate cancer markers.-  Prognostic value of CTC's in urologic cancers.- Management of Small Renal Masses.-  Advances in the Treatment of Metastatic Renal Cell Carcinoma.-Imaging in urologic cancers .-   Molecular prognostication in Bladder cancer.-  Early cystectomy for high risk non-muscle invasive disease.-  Care-coordination pathway after radical cystectomy.-  Current role of checkpoint inhibitors in urologic cancers.- ) The Cancer Genome Atlas Project.-  Prognostic models in germ cell tumors.- Modern management of testicular cancer.

Dr. Sia Daneshmand earned his medical degree at the University of California, Davis and completed his residency at the University of Southern California (USC) followed by a two-year fellowship in Urologic Oncology at the USC/Norris Comprehensive Cancer Center. He spent almost 6 years at Oregon Health and Science University and was then recruited to USC Institute of Urology in 2010 as Director of Urologic Oncology. He is currently an Associate Professor of Urology with Clinical Scholar designation and serves as director of clinical research as well as the urologic oncology (SUO) fellowship director. Dr. Daneshmand's main interests include bladder cancer, advanced kidney cancer and testicular cancer. He has extensive experience in urinary diversion and reconstruction following radical cystectomy as well as nerve-sparing retroperitoneal lymph node dissection (RPLND) following chemotherapy for advanced testis cancer. He is one of the highest volume surgeons for these diseases inthe country. He also has extensive experience in the management of advanced kidney cancers with vena caval tumor thrombus involvement, as well as prostate cancer, retroperitoneal sarcomas and surgeries requiring replacement of the great vessels. His main research interests focus on the use of pathways to improve peri-operative outcomes following radical cystectomy, use of serum and molecular markers and new technologies in diagnosis and management of bladder cancer, as well as functional outcomes following orthotopic urinary diversion.  He is a leading authority on enhanced recovery after surgery (ERAS) following radical cystectomy and his protocol has significantly reduced hospital stay while improving the patient experience. He serves on the editorial board of the Journal of Urology, Bladder Cancer Journal, Current Opinions in Urology, the scientific advisory board of Bladder Cancer Advocacy Network (BCAN) as well as the AUA/SUO Guideline Committee on non-muscle invasive